Clinical Trial Update: Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by CART19 [NA]

View source ↗

Summary

Clinical trial update describing CART19 therapy for relapsed and/or chemotherapy-refractory B-cell malignancies with an unknown status of the trial.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia B-cell
• Chronic Lymphocytic Leukemia
• Diffuse Large B-cell Lymphoma
• Follicular Lymphoma
• Mantle Cell Lymphoma
• Prolymphocytic Leukemia

Drugs mentioned

• CART19 therapy (CD19-targeted chimeric antigen receptor T-cell therapy)

Snippet

Sponsor: Chinese PLA General Hospital | Conditions: Hematopoietic/Lymphoid Cancer, Adult Acute Lymphoblastic Leukemia in Remission | NA | Status: UNKNOWN